ID   OZ [Human cholangiocarcinoma]
AC   CVCL_3118
DR   BioSample; SAMN03472539
DR   Cosmic; 1122353
DR   Cosmic; 1373552
DR   Cosmic; 2629291
DR   Cosmic; 2674046
DR   JCRB; JCRB1032
DR   JCRB; NIHS0282
DR   Wikidata; Q54937185
RX   CelloPub=CLPUB00275;
RX   CelloPub=CLPUB00469;
RX   PubMed=2889643;
RX   PubMed=21451941;
RX   PubMed=26956050;
RX   PubMed=32899426;
RX   PubMed=35640676;
CC   Population: Japanese.
CC   Doubling time: ~48 hours (CelloPub=CLPUB00469; PubMed=2889643).
CC   Omics: Transcriptome analysis by RNAseq.
CC   Discontinued: JCRB; NIHS0282; true.
CC   Derived from site: Metastatic; Ascites; UBERON=UBERON_0007795.
ST   Source(s): JCRB=JCRB1032
ST   Amelogenin: X,Y
ST   CSF1PO: 11,12
ST   D13S317: 8,12
ST   D16S539: 10
ST   D5S818: 13,14
ST   D7S820: 10
ST   TH01: 6,9
ST   TPOX: 9,11
ST   vWA: 14,16
DI   NCIt; C35417; Intrahepatic cholangiocarcinoma
DI   ORDO; Orphanet_70567; Cholangiocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   71Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 02-05-24; Version: 20
//
RX   CelloPub=CLPUB00275;
RA   Zach S., Birgin E., Ruckert F.;
RT   "Primary cholangiocellular carcinoma cell lines.";
RL   J. Stem Cell Res. Transplant. 2:1013-1013(2015).
//
RX   CelloPub=CLPUB00469;
RA   Homma S.;
RT   "Studies on the establishment and some biological characteristics of
RT   cultured human liver cancer cell lines. Their growth, functional and
RT   morphological characteristics and temperature sensitivities.";
RL   Jikeikai Med. J. 32:289-315(1985).
//
RX   PubMed=2889643; DOI=10.1007/BF02773816;
RA   Homma S., Nagamori S., Fujise K., Yamazaki K., Hasumura S., Sujino H.,
RA   Matsuura T., Shimizu K., Kameda H., Takaki K.;
RT   "Human bile duct carcinoma cell line producing abundant mucin in
RT   vitro.";
RL   Gastroenterol. Jpn. 22:474-479(1987).
//
RX   PubMed=21451941; DOI=10.1007/s00534-011-0376-7;
RA   Sato J., Kimura T., Saito T., Anazawa T., Kenjo A., Sato Y.,
RA   Tsuchiya T., Gotoh M.;
RT   "Gene expression analysis for predicting gemcitabine resistance in
RT   human cholangiocarcinoma.";
RL   J. Hepatobiliary Pancreat. Sci. 18:700-711(2011).
//
RX   PubMed=26956050; DOI=10.18632/oncotarget.7914; PMCID=PMC4991440;
RA   Ding X.-W., Chaiteerakij R., Moser C.D., Shaleh H.M., Boakye J.,
RA   Chen G., Ndzengue A., Li Y., Zhou Y.-L., Huang S.-B., Sinicrope F.A.,
RA   Zou X.-P., Thomas M.B., Smith C.D., Roberts L.R.;
RT   "Antitumor effect of the novel sphingosine kinase 2 inhibitor
RT   ABC294640 is enhanced by inhibition of autophagy and by sorafenib in
RT   human cholangiocarcinoma cells.";
RL   Oncotarget 7:20080-20092(2016).
//
RX   PubMed=32899426; DOI=10.3390/cancers12092510; PMCID=PMC7565451;
RA   Scherer D., Davila-Lopez M., Goeppert B., Abrahamsson S.,
RA   Gonzalez Silos R., Nova I., Marcelain K., Roa J.C., Ibberson D.,
RA   Umu S.U., Rounge T.B., Roessler S., Lorenzo-Bermejo J.;
RT   "RNA sequencing of hepatobiliary cancer cell lines: data and
RT   applications to mutational and transcriptomic profiling.";
RL   Cancers (Basel) 12:2510.1-2510.14(2020).
//
RX   PubMed=35640676; DOI=10.1016/j.ajpath.2022.05.007; PMCID=PMC9472155;
RA   Isidan A., Yenigun A., Soma D., Aksu E., Lopez K., Park Y.,
RA   Cross-Najafi A., Li P., Kundu D., House M.G., Chakraborty S.,
RA   Glaser S., Kennedy L., Francis H., Zhang W.-J., Alpini G.D., Ekser B.;
RT   "Development and characterization of human primary cholangiocarcinoma
RT   cell lines.";
RL   Am. J. Pathol. 192:1200-1217(2022).
//